MX2018014475A - Métodos y composiciones para el tratamiento de trastornos secretorios. - Google Patents

Métodos y composiciones para el tratamiento de trastornos secretorios.

Info

Publication number
MX2018014475A
MX2018014475A MX2018014475A MX2018014475A MX2018014475A MX 2018014475 A MX2018014475 A MX 2018014475A MX 2018014475 A MX2018014475 A MX 2018014475A MX 2018014475 A MX2018014475 A MX 2018014475A MX 2018014475 A MX2018014475 A MX 2018014475A
Authority
MX
Mexico
Prior art keywords
treatment
methods
disorders
epi
pancreatitis
Prior art date
Application number
MX2018014475A
Other languages
English (en)
Inventor
J Mangelsdorf David
A Kliewer Steven
C Coate Katie
HERNANDEZ Genaro
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of MX2018014475A publication Critical patent/MX2018014475A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion se refiere al tratamiento de trastornos secretorios y proporciona nuevos metodos de tratamiento de estos trastornos que comprende la administracion de factor de crecimiento de fibroblastos 21 (FGF21) o sus derivados; los metodos de la invencion son utiles en afecciones que incluyen insuficiencia pancreatica exocrina (EPI), por ejemplo, EPI resultante de fibrosis quistica, alcoholismo, pancreatitis, cancer de pancreas, calculos biliares, enfermedad celiaca, trigliceridos elevados o lupus; los metodos de la presente invencion encuentran una utilidad adicional en el tratamiento de trastornos del flujo salival, por ejemplo el sindrome de Sjorgen, y la prevencion de EPI o pancreatitis resultante de procedimientos quirurgicos.
MX2018014475A 2016-05-25 2017-05-24 Métodos y composiciones para el tratamiento de trastornos secretorios. MX2018014475A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662341591P 2016-05-25 2016-05-25
PCT/US2017/034288 WO2017205517A1 (en) 2016-05-25 2017-05-24 Methods and compositions for the treatment of secretory disorders

Publications (1)

Publication Number Publication Date
MX2018014475A true MX2018014475A (es) 2019-05-23

Family

ID=60412662

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014475A MX2018014475A (es) 2016-05-25 2017-05-24 Métodos y composiciones para el tratamiento de trastornos secretorios.

Country Status (8)

Country Link
US (2) US11318186B2 (es)
EP (1) EP3463427A4 (es)
JP (1) JP7023518B2 (es)
CN (1) CN109789186A (es)
CA (1) CA3026510A1 (es)
IL (2) IL282455B (es)
MX (1) MX2018014475A (es)
WO (1) WO2017205517A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018297285A1 (en) 2017-07-06 2020-01-30 Yale University Compositions and methods for treating or preventing endocrine FGF-linked diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
US20040259780A1 (en) * 2001-07-30 2004-12-23 Glasebrook Andrew Lawrence Method for treating diabetes and obesity
WO2011154349A2 (en) * 2010-06-08 2011-12-15 Novo Nordisk A/S Fgf21 analogues and derivatives
JP2012529463A (ja) * 2009-06-11 2012-11-22 ノヴォ ノルディスク アー／エス ２型糖尿病を治療するための、ｇｌｐ−１とｆｇｆ２１との組合せ
KR101900962B1 (ko) 2010-04-09 2018-09-20 큐알엔에이, 인크. 섬유아세포 성장 인자 21 (ｆｇｆ21)에 대한 자연 안티센스 전사체의 저해에 의한 섬유아세포 성장 인자 21 (ｆｇｆ21) 관련된 질환의 치료
TR201716639T3 (tr) 2010-06-08 2019-05-21 Arcelik As Bi̇r kurutucu.
US9023791B2 (en) * 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
KR102077721B1 (ko) 2011-07-01 2020-02-14 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사성 장애 및 질환의 치료를 위한 조성물, 용도 및 방법
UY34347A (es) * 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
TWI593708B (zh) * 2011-09-26 2017-08-01 諾華公司 治療代謝病症之融合蛋白質
US10456449B2 (en) 2014-06-16 2019-10-29 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
IL251834B2 (en) * 2014-10-23 2023-09-01 Ngm Biopharmaceuticals Inc Pharmaceutical compositions containing peptide variants and methods of using them
PL3412302T3 (pl) * 2014-10-24 2021-11-02 Bristol-Myers Squibb Company Zmodyfikowane polipeptydy fgf-21 i ich zastosowania

Also Published As

Publication number Publication date
US11318186B2 (en) 2022-05-03
CN109789186A (zh) 2019-05-21
WO2017205517A1 (en) 2017-11-30
IL282455A (en) 2021-06-30
EP3463427A4 (en) 2020-03-11
IL282455B (en) 2022-08-01
IL263240A (en) 2018-12-31
JP7023518B2 (ja) 2022-02-22
EP3463427A1 (en) 2019-04-10
US20190201490A1 (en) 2019-07-04
CA3026510A1 (en) 2017-11-30
US20220257716A1 (en) 2022-08-18
IL263240B (en) 2021-05-31
JP2019516764A (ja) 2019-06-20

Similar Documents

Publication Publication Date Title
AU2018236800B2 (en) DNA-PK inhibitors
MX2021014007A (es) Proteinas de union a epcam y metodos de uso.
EP4219713A3 (en) Products and compositions
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
MX2018001532A (es) Anticuerpos anti-angptl8 y usos de estos.
MX2019000588A (es) Moduladores de la somatostatina y usos de los mismos.
NZ757081A (en) Somatostatin modulators and uses thereof
MX2013005639A (es) Metodos para el tratamiento de transtornos asociados con fgf21.
MX2019001308A (es) Moduladores nmda espiro-lactam y metodos de uso de los mismos.
MY173795A (en) Novel benzopyran kinase modulators
MX2018012873A (es) Composiciones y métodos para el tratar enfermedades asociadas con repeticiones de trinucleótidos en el factor de transcripción cuatro.
MX2019004859A (es) Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas.
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
MX2023001877A (es) Meganucleasas dise?adas especificas para secuencias de reconocimiento en el gen pcsk9.
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
MX2019009952A (es) Formulaciones de evolocumab de baja viscosidad y alta concentracion y metodos de elaboracion de las mismas.
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
MX2020007586A (es) Proceso de fabricacion de moduladores de somatostatina.
NZ756936A (en) Composition and method for preventing or delaying onset of myopia comprising atropine
MX2021013602A (es) Inhibidores de jak.
MX342119B (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2022000712A (es) Moduladores de nlrp3.
EP4041209A4 (en) TRANSDERMAL COMPOSITIONS CONTAINING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF SEIZURE DISORDERS
PH12020551071A1 (en) Compositions and methods for treating retinal disorders
MX2021008941A (es) Moduladores gpr35.